Literature DB >> 1810306

Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase.

J C Craig1, I B Duncan, D Hockley, C Grief, N A Roberts, J S Mills.   

Abstract

Ro 31-8959 inhibits the spread of HIV infection and the production of cytopathic effects in cultures of acutely infected cells. IC50 values for these effects are in the range 0.5-6.0 nM and IC90 values are in the range 6.0-30.0 nM. This inhibitor is effective even when added to cultures at a late stage of infection, after syncytia have started to form. Virus antigen, virus particles and virus cytopathic effects can largely be cleared from cultures treated with compound from 3 days until 6 days post infection. In chronically-infected cells, inhibition of virus maturation can be detected after 24 hours' treatment with 10 nM Ro 31-8959. In addition, a significant reduction of the proteolytic processing of p56 to p24 can be demonstrated in these cells with compound at picomolar concentrations. These properties indicate that Ro 31-8959 is highly effective against HIV with the potential to inhibit acute, established acute and chronic infections.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1810306     DOI: 10.1016/0166-3542(91)90045-s

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  39 in total

1.  Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease.

Authors:  H Jacobsen; L Ahlborn-Laake; R Gugel; J Mous
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

2.  HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants.

Authors:  Michael D Altman; Akbar Ali; G S Kiran Kumar Reddy; Madhavi N L Nalam; Saima Ghafoor Anjum; Hong Cao; Sripriya Chellappan; Visvaldas Kairys; Miguel X Fernandes; Michael K Gilson; Celia A Schiffer; Tariq M Rana; Bruce Tidor
Journal:  J Am Chem Soc       Date:  2008-04-16       Impact factor: 15.419

3.  Characterizing Protein-Ligand Binding Using Atomistic Simulation and Machine Learning: Application to Drug Resistance in HIV-1 Protease.

Authors:  Troy W Whitfield; Debra A Ragland; Konstantin B Zeldovich; Celia A Schiffer
Journal:  J Chem Theory Comput       Date:  2020-01-16       Impact factor: 6.006

4.  Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults.

Authors:  J M Kilby; G Sfakianos; N Gizzi; P Siemon-Hryczyk; E Ehrensing; C Oo; N Buss; M S Saag
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

5.  The role of HIV-proteinase inhibitors.

Authors:  B Gazzard; G Moyle
Journal:  Genitourin Med       Date:  1996-08

6.  3'-Tetrahydrofuranylglycine as a Novel, Unnatural Amino Acid Surrogate for Asparagine in the Design of Inhibitors of the HIV Protease.

Authors:  Wayne J Thompson; Arun K Ghosh; M Katharine Holloway; Hee Yoon Lee; Peter M Munson; John E Schwering; Jenny Wai; Paul L Darke; Joan Zugay; Emilio A Emini; William A Schleif; Joel R Huff; Paul S Anderson
Journal:  J Am Chem Soc       Date:  1993-01-01       Impact factor: 15.419

7.  Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro.

Authors:  A R Bender; H von Briesen; J Kreuter; I B Duncan; H Rübsamen-Waigmann
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

8.  S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1.

Authors:  T Fujiwara; A Sato; M el-Farrash; S Miki; K Abe; Y Isaka; M Kodama; Y Wu; L B Chen; H Harada; H Sugimoto; M Hatanaka; Y Hinuma
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  Lack of immunotoxicity of saquinavir (Ro 31-8959) used alone or in double or triple combination with AZT and ddC.

Authors:  M Viora; G Di Genova; M G Quaranta; M Boirivant; B Camponeschi
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

10.  Drug-resistant molecular mechanism of CRF01_AE HIV-1 protease due to V82F mutation.

Authors:  Xiaoqing Liu; Zhilong Xiu; Ce Hao
Journal:  J Comput Aided Mol Des       Date:  2009-02-15       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.